312 results on '"Engl W"'
Search Results
2. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
3. Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A
4. Hemmkörper-Hämophilie A: Induktion einer Immuntoleranz mit IMMUNATE STIM plus
5. On the Influence of Thermal Diffusion and Heat Flux on Bipolar Device and Circuit Performance
6. Impact Ionization for Electrons in Si with Monte Carlo Simulation
7. Factors influencing the pharmacokinetics of pegylated recombinant factor VIII (BAX 855) administered for prophylaxis in previously treated patients with severe hemophilia A: OR215
8. Assessing goodness-of-fit for evaluation of dose-proportionality
9. Cantilever probes for high speed AFM
10. Recent improvements in the integration of field emitters into scanning probe microscopy sensors
11. Controlled production of emulsions and particles by milli- and microfluidic techniques
12. A droplet-based high-throughput tubular platform to extract rate constants of slow chemical reactions
13. Millifluidic as a versatile reactor to tune size and aspect ratio of large polymerized objects
14. Piezoresistive and self-actuated 128-cantilever arrays for nanotechnology applications
15. Filling the gap on long-term joint health and HRQoL outcomes data in hemophilia A using a single product (rAHF-PFM), non-interventional registry, AHEAD: PO 158
16. The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy
17. Detection of non-inhibitory binding antibodies to von Willebrand factor affecting the clearance of VWF:Ag in von Willebrand disease: PO-MO-255
18. Advate hemophlia a outome database (AHEAD): A long-term registry focusing on joint health outcomes and health-related quality of life: PO-TU-150
19. Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients: 821
20. Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD): 50
21. New Immune Globulin Subcutaneous (Human), 10% (IGSC) Product is Well Tolerated in Subjects with Primary Immunodeficiency Diseases (PIDD): 48
22. Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients: 44
23. Efficacy Analysis of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD): 45
24. A new early prophylaxis regimen that avoids immunological danger signals can reduce factor eight (FVIII) inhibitor development independent from product type used: 17P11
25. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development
26. Electrical percolation in the presence of attractive interactions: An effective medium lattice approach applied to microemulsion systems
27. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies
28. Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study
29. Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A
30. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia
31. Immunoglobulin home therapy using subcutaneous Ig every week gives higher trough levels than equal amounts of intravenous Ig every second week
32. An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients
33. Innocuité et tolérabilité de l’immunoglobuline humaine G à 20 %, administrée par voie sous-cutanée (Ig20Gly) : analyse finale d’une étude de phase 2/3 portant sur des patients souffrant de déficits immunitaires primitifs (DIP) en Europe
34. Innocuité et tolérabilité d’une préparation d’immunoglobuline humaine sous-cutanée à 20 % chez des patients pédiatriques âgés < 16 ans souffrant de déficits immunitaires primitifs (DIP) en Europe et en Amérique du Nord
35. Impact Ionization for Electrons in Si with Monte Carlo Simulation
36. High-purity factor concentrates in prevention of AIDS
37. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability
38. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A
39. O015 Tolerability of a new human immune globulin subcutaneous, 20% preparation in primary immunodeficiency diseases
40. P251 Safety/tolerability of human immune globulin subcutaneous, 20% in pediatric patients with primary immunodeficiency diseases
41. P257 Treatment preference among patients with primary immunodeficiency diseases (PIDD) on investigational 20% subcutaneous immunoglobulin therapy
42. P254 Local adverse reactions decreased over time during IGHY treatment in patients with PIDD
43. An improved impact-ionization model for high-energy electron transport in Si with Monte Carlo simulation.
44. Recruitment update of AHEAD
45. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial
46. Identifikation von Mehrgrößensystemen mit beliebigen Einschwingvorgängen: Anwendung auf einen supraleitenden Synchrongenerator
47. Der induktive Durchflußmesser mit inhomogenem Magnetfeld: Teil I. Allgemeine Grundlagen und Lösung des ebenen Problems
48. Mengentheorie verallgemeinerter Graphen
49. Weiterführung der Sobreroschen Theorie des ebenen Spannungszustandes
50. Zur Methodik der Gegenkopplungsschaltungen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.